- North American Vaccine and Abbott Laboratories have signed an agreement in principle for Abbott to market NAV's diphtheria, tetanus and acellular pertussis vaccine (DTPa) once it gains approval in the USA. NAV filed an application to market the vaccine in September 1995. The deal also includes an option on NAV's DTPa vaccines plus inactivated polio and Hemophilus influenzae type-b antigens. Under the terms of the deal, Abbott will make an investment of around $42 million in NAV, which will include an equity stake, licensing, development and milestone payments, and royalties on sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze